Treatment of gastroenteropancreatic neuroendocrine tumors

被引:0
作者
U. Plöckinger
B. Wiedenmann
机构
[1] Universitätsmedizin Berlin,Interdiziplinäres Stoffwechsel
[2] Campus Virchow-Klinikum,CentrumCharité
来源
Virchows Archiv | 2007年 / 451卷
关键词
Gastroenteropancreatic neuroendocrine tumors; Biotherapy; Somatostatin analogue; Interferon; Chemotherapy; Streptozotocin; Tyrosine kinase inhibitor; Anti-angiogenic therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Neuroendocrine tumors are rare; thus, individual experience with the diagnosis and treatment of these tumors is mostly low, except in specialized centers. For histological diagnosis, standards have been described recently. Pathological classification and clinical staging influence diagnostic and therapeutic decisions. This chapter aims at demonstrating the importance of pathological and clinical classification of neuroendocrine tumors on therapeutic decisions, indicating the appropriate therapy for different stages of the disease. Surgical therapy will be discussed shortly, including palliative surgical strategies. However, the focus of the manuscript is medical therapy. Biotherapy, its effects, and remaining uncertainties are presented as well as different chemotherapeutic schemes. Finally, new options of palliative medical therapies like kinase inhibitors and anti-angiogenetic drugs will be discussed.
引用
收藏
页码:71 / 80
页数:9
相关论文
共 449 条
[1]  
Anthony L(1993)Somatostatin analogue phase I trials in neuroendocrine neoplasms Acta Oncol 32 217-223
[2]  
Johnson D(2001)Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours Eur J Cancer 37 1014-1019
[3]  
Hande K(1993)Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group Digestion 54 72-75
[4]  
Shaff M(1993)Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors World J Surg 17 511-519
[5]  
Winn S(1996)Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours Gut 38 430-438
[6]  
Krozely M(1998)5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors Cancer 83 372-378
[7]  
Oates J(2002)Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours Ann Oncol 13 614-621
[8]  
Aparicio T(1992)Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study J Clin Oncol 10 1914-1918
[9]  
Ducreux M(1999)Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma Cancer 86 944-948
[10]  
Baudin E(2004)Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis Pharmacol Ther 102 61-85